Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 14 studies | 41% ± 13% | |
peripheral blood | 13 studies | 33% ± 15% | |
intestine | 10 studies | 51% ± 22% | |
kidney | 7 studies | 39% ± 16% | |
eye | 6 studies | 30% ± 22% | |
uterus | 5 studies | 73% ± 9% | |
lymph node | 5 studies | 42% ± 11% | |
prostate | 4 studies | 30% ± 5% | |
breast | 4 studies | 58% ± 15% | |
placenta | 3 studies | 44% ± 12% | |
bone marrow | 3 studies | 41% ± 11% | |
adrenal gland | 3 studies | 39% ± 19% | |
esophagus | 3 studies | 45% ± 25% | |
skin | 3 studies | 39% ± 13% | |
thymus | 3 studies | 38% ± 7% | |
liver | 3 studies | 31% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 68% | 14716.28 | 123 / 180 | 53% | 55.06 | 228 / 430 |
lung | 60% | 13115.22 | 344 / 578 | 51% | 47.14 | 591 / 1155 |
thymus | 35% | 4020.72 | 229 / 653 | 74% | 181.15 | 447 / 605 |
prostate | 37% | 1551.66 | 90 / 245 | 72% | 158.29 | 359 / 502 |
stomach | 55% | 13792.98 | 197 / 359 | 48% | 28.60 | 138 / 286 |
breast | 56% | 6649.73 | 258 / 459 | 47% | 39.65 | 522 / 1118 |
bladder | 48% | 9232.90 | 10 / 21 | 53% | 53.14 | 269 / 504 |
esophagus | 33% | 3915.78 | 476 / 1445 | 66% | 54.70 | 120 / 183 |
skin | 71% | 19849.35 | 1278 / 1809 | 25% | 14.77 | 116 / 472 |
intestine | 43% | 4846.03 | 412 / 966 | 44% | 25.33 | 233 / 527 |
pancreas | 21% | 1042.04 | 69 / 328 | 62% | 57.71 | 111 / 178 |
adrenal gland | 31% | 2157.24 | 79 / 258 | 53% | 61.27 | 121 / 230 |
uterus | 21% | 4892.49 | 36 / 170 | 50% | 56.97 | 231 / 459 |
kidney | 22% | 1082.85 | 20 / 89 | 49% | 73.75 | 437 / 901 |
tonsil | 0% | 0 | 0 / 0 | 60% | 55.97 | 27 / 45 |
adipose | 55% | 26100.19 | 659 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 52% | 8134.29 | 698 / 1335 | 0% | 0 | 0 / 0 |
brain | 15% | 967.25 | 394 / 2642 | 31% | 16.34 | 217 / 705 |
liver | 23% | 1093.65 | 52 / 226 | 18% | 9.57 | 72 / 406 |
heart | 39% | 3940.21 | 335 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 13% | 393.02 | 124 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 10% | 2.09 | 3 / 29 |
spleen | 10% | 459.56 | 24 / 241 | 0% | 0 | 0 / 0 |
muscle | 3% | 157.65 | 24 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.31 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0043278 | Biological process | response to morphine |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0032870 | Biological process | cellular response to hormone stimulus |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0045471 | Biological process | response to ethanol |
GO_0007565 | Biological process | female pregnancy |
GO_0071277 | Biological process | cellular response to calcium ion |
GO_0051591 | Biological process | response to cAMP |
GO_0001975 | Biological process | response to amphetamine |
GO_0009612 | Biological process | response to mechanical stimulus |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0048148 | Biological process | behavioral response to cocaine |
GO_0051412 | Biological process | response to corticosterone |
GO_0032570 | Biological process | response to progesterone |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FOSB |
Protein name | FOSB protein FosB proto-oncogene, AP-1 transcription factor subunit Protein FosB (FosB proto-oncogene, AP-1 transcription factor subunit) (G0/G1 switch regulatory protein 3) (Transcription factor AP-1 subunit FosB) |
Synonyms | G0S3 |
Description | FUNCTION: Heterodimerizes with proteins of the JUN family to form an AP-1 transcription factor complex, thereby enhancing their DNA binding activity to gene promoters containing an AP-1 consensus sequence 5'-TGA[GC]TCA-3' and enhancing their transcriptional activity . As part of the AP-1 complex, facilitates enhancer selection together with cell-type-specific transcription factors by collaboratively binding to nucleosomal enhancers and recruiting the SWI/SNF (BAF) chromatin remodeling complex to establish accessible chromatin (By similarity). Together with JUN, plays a role in activation-induced cell death of T cells by binding to the AP-1 promoter site of FASLG/CD95L, and inducing its transcription in response to activation of the TCR/CD3 signaling pathway . Exhibits transactivation activity in vitro (By similarity). Involved in the display of nurturing behavior towards newborns (By similarity). May play a role in neurogenesis in the hippocampus and in learning and memory-related tasks by regulating the expression of various genes involved in neurogenesis, depression and epilepsy (By similarity). Implicated in behavioral responses related to morphine reward and spatial memory (By similarity). .; FUNCTION: [Isoform 11]: Exhibits lower transactivation activity than isoform 1 in vitro (By similarity). The heterodimer with JUN does not display any transcriptional activity, and may thereby act as an transcriptional inhibitor (By similarity). May be involved in the regulation of neurogenesis in the hippocampus (By similarity). May play a role in synaptic modifications in nucleus accumbens medium spiny neurons and thereby play a role in adaptive and pathological reward-dependent learning, including maladaptive responses involved in drug addiction (By similarity). Seems to be more stably expressed with a half-life of ~9.5 hours in cell culture as compared to 1.5 hours half-life of isoform 1 (By similarity). . |
Accessions | ENST00000590335.1 ENST00000417353.6 [P53539-2] ENST00000443841.6 [P53539-8] Q6FGK6 K7EJ89 ENST00000585836.5 [P53539-5] K7EKA0 P53539 K7ERZ8 ENST00000591858.5 [P53539-3] ENST00000589593.1 ENST00000592436.5 [P53539-11] ENST00000586615.5 [P53539-10] A1L186 ENST00000592811.5 ENST00000353609.8 [P53539-1] |